Details der Publikation - Nasal spray of mometasone 0.05% effects on olfactory improvement in COVID-19

Medienart:	Klinische Studie

Erscheinungsjahr:	2021
Erschienen:	2021

Enthalten in:	WHO International Clinical Trials Registry Platform - (2021) vom: 22. Feb. Zur Gesamtaufnahme - year:2021

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Anosmia. Anosmia;R43.0 Phase: Phase 2/Phase 3 Recruitment Status: Recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2021-02-20, Last updated: 2022-11-24

ICTRP ID:	IRCT20190804044429N6

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO007512295


LEADER	01000caa a22002652 4500
001	WHO007512295
003	DE-627
005	20230425171738.0
007	cr uuu---uuuuu
008	210512s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO007512295
035			\|a (UBBS_Klinische_Studien_WHO)IRCT20190804044429N6
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Nasal spray of mometasone 0.05% effects on olfactory improvement in COVID-19 \|b Efficacy and safety of nasal spray of mometasone 0.05%on olfactory improvement in patients with COVID-19: A randomized, double blind clinical trial
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2021-02-20, Last updated: 2022-11-24
650		4	\|a Medical Condition: Anosmia. Anosmia;R43.0
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2/Phase 3
650		4	\|a Recruitment Status: Recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2021) vom: 22. Feb.
773	1	8	\|g year:2021 \|g day:22 \|g month:02
856	4	0	\|u http://en.irct.ir/trial/54008 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2021 \|b 22 \|c 02